# Synapse — News, Sentiment & Analysis **Source:** TrendWatcher — https://www.trendwatcher.in/topic/synapse **As of:** 2026-09-16 (UTC) **Sentiment:** neutral (50/100) **Sources analysed:** 8 As of 2026-09-16, TrendWatcher scores Synapse sentiment as **neutral** at 50/100, based on 8 news sources analysed over the past 24 hours. ## Summary Synapse, a fintech intermediary backed by Andreessen Horowitz, has entered bankruptcy, revealing an $85 million shortfall between partner banks' holdings and depositor balances. Trustee Jelena McWilliams reports that customers of fintech firms using Synapse had $265 million in balances, while the banks held only $180 million, leaving over 100,000 users locked out of their accounts and prompting a complex reconciliation effort across multiple banks. Separately, SYNAPSE-CMT is a Phase 2a clinical trial by NMD Pharma evaluating the investigational drug ignaseclant for Charcot‑Marie‑Tooth disease. The trial enrolled 81 adults and reported functional improvements and tolerability, with benefits persisting after treatment cessation, supporting further investigation of the therapy. ## Key points - The Synapse bankruptcy shows an $85 million gap between bank-held funds and customer deposits, affecting over 100,000 fintech users. - Trustee McWilliams is working with four banks to reconcile ledgers, but missing funds and the movement of balances remain unclear. - NMD Pharma's SYNAPSE-CMT Phase 2a trial enrolled 81 patients and demonstrated improvements in muscle strength and functional measures with ignaseclant. - Ignaseclant was well tolerated, with only mild to moderate adverse events and no serious events reported. - The trial's results suggest a potential lasting effect on neuromuscular function, prompting plans for larger, longer-term studies. ## Frequently asked questions ### What caused the shortfall in the Synapse bankruptcy? A report by trustee Jelena McWilliams indicates an $85 million discrepancy between the $265 million in customer balances and the $180 million held by partner banks, but the exact source of the missing funds is still unknown. ### How many customers are affected by the Synapse fallout? More than 100,000 customers of various fintech companies that used Synapse have been locked out of their savings accounts. ### What were the primary outcomes of the SYNAPSE-CMT trial? The trial showed consistent signals of benefit in functional endpoints, including improved hand grip strength and motor function, with effects persisting up to seven days after treatment ended. ### Is ignaseclant safe for patients? Ignaseclant was reported as well tolerated, with all adverse events classified as mild or moderate and no serious adverse events or discontinuations. ### What are the next steps for ignaseclant development? NMD Pharma plans to conduct larger and longer-term studies to further evaluate ignaseclant’s efficacy and safety in Charcot‑Marie‑Tooth disease. ## Latest coverage - [Synapse bankruptcy trustee reports $85 million missing from customer](https://www.trendwatcher.in/article/ca70bf6e-c5eb-4faf-b615-077122614361) — neutral, 2026-06-18: Synapse trustee Jelena McWilliams finds $85 million gap between $265 million owed and $180 million held, affecting over 100,000 fintech users. - [TabaPay to Acquire Synapse Assets for $9.7 million](https://www.trendwatcher.in/article/da6724ed-bf92-437d-ad89-cf482f5191eb) — neutral, 2026-06-18: TabaPay agrees to buy Synapse’s banking‑as‑a‑service assets for $9.7 M pending Chapter 11 approval, expanding its fintech suite. - [Synapse bankruptcy threatens 10 million fintech accounts, CFPB to pay](https://www.trendwatcher.in/article/77e20b32-edd4-4e81-9fb3-b1447311f3a2) — neutral, 2026-06-18: Synapse collapse puts over 10 million accounts at risk; CFPB will reimburse $46 M to victims of Yotta, Juno, Copper and other fintechs. - [CFPB moves to use Civil Penalty Fund for Synapse customer losses](https://www.trendwatcher.in/article/8d249585-afd7-4574-8602-4cbafc99ea79) — neutral, 2026-06-18: CFPB seeks to convert Synapse bankruptcy to Chapter 7 and tap its $118.9 M penalty fund to reimburse $60‑90 M missing fintech customer funds. - [NMD Pharma presents SYNAPSE‑CMT Phase 2a data at 2026 PNS Annual](https://www.trendwatcher.in/article/59a11e15-ae82-403c-b4dd-54b8e2b528c1) — neutral, 2026-06-18: NMD Pharma’s Phase 2a ignaceclant trial in Charcot‑Marie‑Tooth shows functional gains and safety, presented June 14 2026 at the PNS meeting. - [Synapse collapse leaves Mercury scrambling for creditor priority](https://www.trendwatcher.in/article/abf6044b-fc95-44ae-ae38-1539ef0e5854) — neutral, 2026-06-18: Synapse bankruptcy froze $200 million in customer assets and erased $95 million; Mercury moves to outrank other claimants as lawsuits mount. - [CFPB may tap Civil Penalty Fund to reimburse Synapse fintech customers](https://www.trendwatcher.in/article/a55cfa84-a23e-4cbe-8ebd-ae191ac91a7c) — neutral, 2026-06-18: CFPB signals use of its $1‑nominal penalty fund to return up to $95 million lost by fintech users after Synapse’s bankruptcy, offering a path to recovery. - [Senators blame VC investors in Synapse collapse, demand fund access](https://www.trendwatcher.in/article/c34d32d5-5a79-463d-b8df-0c91751bfc4d) — neutral, 2026-06-18: Senators urge Synapse’s VC backers and partners to restore frozen customer funds, citing $65‑$96 million shortfall and BaaS oversight failures. --- Cite as: TrendWatcher, "Synapse — News, Sentiment & Analysis", https://www.trendwatcher.in/topic/synapse (retrieved 2026-09-16).